stereotactic body radiation therapy (SBRT) use has increased overtime for the management of metastatic renal cell carcinoma (mRCC) patients, with a likely good control of irradiated lesions. We planned a retrospective multicenter Italian study, with the aim of investigating the outcome of treatment with SBRT for non-brain secondary lesions in mRCC patients.

all consecutive metastatic non-brain lesions from mRCC that underwent SBRT at nine Italian institutions from January 2015 to June 2017 were considered. The primary endpoint of the study was the lesion-PFS, calculated from SBRT initiation to the local progression of the irradiated lesion.

57 extracranial metastatic lesions from 48 patients with primary mRCC were treated with SBRT. At the median follow-up of 26.4 months, the median lesion-PFS was not reached (43 censored); 72.4% of lesions were progression-free at 40 months, with significantly better lesion-PFS for small metastatic lesions (<14 mm). SBRT was safe and the 1-year local disease control was 87.7%. After SBRT, 18 patients (37.5%) permanently interrupted systemic therapy.

consistently with the previous literature, our findings support the use of SBRT in selected mRCC patients.

Cancer treatment and research communications. 2019 Sep 29 [Epub ahead of print]

Sebastiano Buti, Melissa Bersanelli, Alessandro Viansone, Alessandro Leonetti, Cristina Masini, Raffaele Ratta, Giuseppe Procopio, Francesca Maines, Roberto Iacovelli, Chiara Ciccarese, Maria Giuseppa Vitale, Ugo De Giorgi, Claudia Mucciarini, Marco Maruzzo, Giuseppe Prati, Elisabetta Lattanzi, Patrizia Ciammella, Alessio Bruni, Stefano Andreani, Nunziata D’Abbiero

Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Medicine and Surgery Department, University of Parma, Parma, Italy. Electronic address: ., Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS, Reggio Emilia, Italy., SS Oncologia Genitourinaria Fondazione Istituto Nazionale Tumori Milano, Milano, Italy., Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d’Oro, Trento, Italy., Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy., Department of Oncology and Haematology and Respiratory Disease, University Hospital of Modena, Modena, Italy., Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Medical Oncology Department, Ramazzini Hospital – AUSL Modena, Carpi, Italy., Medical Oncology Unit 1, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy., Day Hospital Oncology, Ospedale Civile di Guastalla, Reggio Emilia, Reggio Emilia, Italy., Radiotherapy Unit, University Hospital of Parma, Parma, Italy., Radiotherapy Unit, Clinical Cancer Centre, AUSL-IRCCS, Reggio Emilia, Italy., Radiation Oncology Unit,University Hospital of Modena, Modena, Italy.